基于诱导多能干细胞的高内涵筛选平台在药物研发中的应用  

Induced pluripotent stem cell based high content screening in drug discovery

作　　者：安世民[1,2] 丁旭苹 朱亮[1,2] 

机构地区：[1]上海交通大学医学院药理学教研室,上海200025 [2]上海交通大学医学院转化医学协同创新中心,上海200025

出　　处：《中国新药杂志》2015年第2期171-176,共6页Chinese Journal of New Drugs

基　　金：国家自然科学基金(81173084);上海市自然科学基金(12ZR1415700);上海市教委科研创新基金(14YZ032)

摘　　要：制药企业药物研发的效率近年来呈逐年下降的趋势,迫切需要更加经济有效的研发平台提高药物研发的成功率。近些年发展起来的诱导多能干(induced pluripotent stem,i PS)细胞技术已日趋成熟,其与传统药物研发模型相比具有众多优势;高内涵筛选(high content screening,HCS)可以在一次实验中获得大量数据信息,是一项重要的药物筛选和研究工具。本文介绍了结合i PS细胞与HCS技术,应用于药物研发的不同阶段和领域,为新药的研发提供更多的潜能。The efficiency of drug discovery is gradually decreasing in past several decades,so more powerful and economic discovery platforms are needed to increase the pharmaceutical industry output. Compared to traditional drug discovery model,the maturing induced pluripotent stem（ i PS） cell technology developed in recent years has many advantages. Meanwhile,high content screening（ HCS） technology,which can obtain large amounts of information from one experiment,became an indispensable tool for drug research and development. This paper describes the utilization of the combination of iPS cells with HCS technology to explore their potential for the development of new drugs.

关 键 词：诱导多能干细胞 高内涵筛选 药物研发 

分 类 号：R972[医药卫生—药品]